JSP191

DRUG3 trials

Sponsors

Porteus, Matthew, MD, National Institute of Allergy and Infectious Diseases (NIAID), Jasper Therapeutics, Inc.

Conditions

CGDChronic Granulomatous DiseaseFanconi AnemiaLower-risk Myelodysplastic Syndrome

Early Phase 1

Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

Active, not recruitingNCT05600907

National Institute of Allergy and Infectious Diseases (NIAID)CGD, Chronic Granulomatous Disease

Start: 2023-01-02End: 2036-11-30Updated: 2026-08-27

Phase 1

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

RecruitingNCT04784052

Porteus, Matthew, MDFanconi Anemia

Start: 2021-12-07End: 2028-12-01Target: 18Updated: 2026-01-27

JSP191 (briquilimab) in Subjects with LR-MDS

TerminatedNCT05903274

Jasper Therapeutics, Inc.Lower-risk Myelodysplastic Syndrome

Start: 2023-06-19End: 2024-10-21Updated: 2025-02-27

Related Papers

Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial

Nature Medicine2025-07-225 citations

Evaluation of Bone Marrow in Fanconi Anemia Patients Treated with Briquilimab Antibody-Based Conditioning and TCRαβ+ T-Cell/CD19+ B-Cell Depleted Haploidentical Grafts

Blood2024-11-05